A clinical trial evaluating the detection of minimal residual disease (MRD) in patients with chronic myeloid leukemia by DNA-PCR

A clinical trial evaluating the detection of minimal residual disease (MRD) in patients with chronic myeloid leukemia by DNA-PCR - Clinical trial evaluating detection of minimal residual disease in patients with chronic myeloid leukemia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006489

Enrollment

Registered

2011-10-05

Start date

2011-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic myeloid leukemia

Interventions

Measurement of BCR-ABL genomic DNA in peripheral blood samples (DNA- PCR method)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic Myeloid Leukemia

Exclusion criteria

Exclusion criteria: Patients whose bone marrow cells or paraffin-embedded tissue prior to the treatment are not available

Design outcomes

Primary

Measure	Time frame
Amount of BCR-ABL genomic DNA in peripheral blood collected during drug treatment (DNA-PCR method)	—

Countries

Japan

Contacts

Public ContactEriko Sato

Juntendo University School of Medicine Department of Hematology

ersato@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026